On September 19, 2023, John Kirby, a representative for the National Security Council, conveyed the United States’ strong desire to restore military-to-military communication channels with China. Kirby emphasized the significance of reopening this crucial line of communication, highlighting it as a priority for the U.S. government. Despite the existing tensions between the two nations, diplomats from both sides have managed to maintain communication channels. However, China has deliberately blocked military communication since the visit of then-House Speaker Nancy Pelosi to Taiwan in August. The United States has voiced concerns regarding China’s military activities, particularly the incursion of a Chinese spy balloon that discreetly flew over sensitive American military installations, gathering intelligence despite U.S. efforts to prevent it. Remarkably, the U.S. has refrained from formally requesting Beijing to arrange a call between President Joe Biden and Chinese President Xi Jinping.
ZIVO Bioscience, Inc.
ZIVO
Neutral
Updated on: 28/09/2023
Financial Health
Weak
Debt to equity ratio: Strong Sell
Price to earnings ratio: Sell
Price to book ratio: Strong Sell
DCF: Strong Buy
ROE: Strong Buy
ZIVO Bioscience, Inc.: Biotechnology Company Focused on Natural Compounds and Algae-Derived Molecules
ZIVO Bioscience, Inc. (ZIVO) is a biotechnology company that focuses on the development and commercialization of natural compounds and bioactive molecules derived from algae. On September 19, 2023, ZIVO stock opened at $1.40, slightly higher than the previous day’s closing price of $1.30. Throughout the day, the stock remained within a narrow range of $1.40 to $1.40. The trading volume was relatively low, with only 1,905 shares being traded, significantly lower than the average volume of 11,134 shares over the past three months.
ZIVO Bioscience has a market capitalization of $14.4 million, indicating that it is a small-cap company. The company has demonstrated positive earnings growth of 22.70% in the previous year. However, there is no information available regarding its earnings growth for the current year or the next five years. Similarly, there is no data on the revenue growth of the company in the previous year.
The price-to-earnings (P/E) ratio for ZIVO stock is not available (NM), suggesting that the company may not have positive earnings or earnings per share (EPS) to calculate the ratio. Additionally, there is no information on the price/sales or price/book ratios for the stock.
Looking at the performance of other stocks in the health technology industry on September 19, 2023, we can see that BCELAtreca Inc experienced a decrease of 0.01 (-1.97%), AEZSAeterna Zentaris Inc had an increase of 0.07 (+2.59%), NMGXNano Magic Inc saw a significant increase of 0.11 (+12.73%), and ORGSOrgenesis Inc had a decrease of 0.07 (-9.46%).
ZIVO Bioscience last reported its financial results on May 31, 2023. The company is expected to report an EPS of -$0.24 for the current quarter. In the previous year, ZIVO Bioscience reported zero annual revenue and a net loss of -$8.7 million.
Unfortunately, there is no information available regarding the net profit margin of the company. However, considering its focus on the health technology sector and the biotechnology industry, ZIVO Bioscience operates in a field that has the potential for significant growth and innovation.
ZIVO Bioscience is headquartered in Bloomfield Hills, Michigan. While there are no executives listed for the company, it is important to note that the success of a biotechnology company often depends on the expertise and leadership of its management team.
In conclusion, on September 19, 2023, ZIVO Bioscience’s stock opened at $1.40, showing a slight increase from the previous day’s closing price. The stock traded within a narrow range throughout the day, with low trading volume. The company has demonstrated positive earnings growth in the previous year, but there is no information available on its earnings or revenue growth for the current and future years. ZIVO Bioscience operates in the health technology sector and the biotechnology industry, which provides opportunities for growth and innovation. However, it is important to consider the company’s financial performance and leadership when evaluating its potential for investment.
Zivo Bioscience Inc: Promising Stock Performance and Positive Projections Make it a Strong Investment Option
Zivo Bioscience Inc, a biotechnology company, has been gaining attention from investors due to its promising stock performance. According to data from CNN Money, the company’s stock has shown positive signs, with analysts projecting a significant increase in its value.
The 12-month price forecasts provided by one analyst for Zivo Bioscience Inc have a median target of $6.00, with both the high and low estimates also at $6.00. This suggests a potential increase of 328.57% from the last recorded price of $1.40.
Moreover, the consensus among one polled investment analyst is to buy stock in Zivo Bioscience Inc. This rating has remained steady since May, indicating that the company’s positive outlook has been consistent and unchanged.
The latest financial data available for Zivo Bioscience Inc shows that the company reported a loss of $0.24 per share in the current quarter. However, it is important to note that the company reported no sales during this period.
Overall, Zivo Bioscience Inc appears to be a promising investment option based on the positive stock performance projections and the consensus among investment analysts. The company’s focus on biotechnology and potential for significant growth make it an attractive choice for investors looking for long-term opportunities. However, it is important for investors to conduct thorough research and consider their own risk tolerance before making any investment decisions.
Discussion about this post